Ironwood Pharmaceuticals, Inc. revised earnings guidance for the year 2022. For the year, the company expects total revenue of $411 million compared to previous guidance rang of $420 million - $430 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.08 USD | -0.25% | +6.32% | -29.37% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.37% | 1.27B | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2022